ZNTL Profile
Zentalis Pharmaceuticals Inc (ZNTL) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for the treatment of cancers and other diseases. The company's pipeline includes a range of drug candidates targeting various cancers, including breast cancer, prostate cancer, and hematologic malignancies.
Zentalis' lead drug candidate is ZN-c5, an oral selective estrogen receptor degrader (SERD) being developed for the treatment of estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer. The company is also developing ZN-d5, an oral WEE1 inhibitor for the treatment of advanced solid tumors, and ZN-e4, an oral small molecule inhibitor of BCL-2 for the treatment of hematologic malignancies.
In addition to its clinical-stage programs, Zentalis is also conducting preclinical research on a range of drug candidates targeting other cancers and diseases, including solid tumors, leukemia, lymphoma, and autoimmune diseases. The company's drug development approach is focused on identifying and targeting specific molecular pathways that are involved in the growth and progression of cancer cells.
Zentalis is headquartered in New York City and was founded in 2014. The company went public in February 2020 and is traded on the Nasdaq Global Market under the ticker symbol "ZNTL".
|
